相关实验视频
Updated: Jul 22, 2026

13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
17.7K
针对神经退行性疾病的乳酸铁素重定向药物的计算选
Mohammed Alrouji1, Mohammed S Alshammari2, Fahad Alhumaydhi3
1Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
Journal of Alzheimer's disease : JAD
|July 18, 2025
概括
这项研究重新定位了FDA批准的药物,以针对神经退行性疾病的乳酸铁素 (LTF). 莫萨普拉和奎努普拉显示出调节LTF活动的潜力,提供了一个新的治疗途径.
科学领域:
- 生物化学和分子生物学
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
背景情况:
- 乳酸 (LTF) 是一种糖蛋白,对铁的平衡,氧化应激和炎症至关重要.
- 像阿尔茨海默氏症和帕金森症这样的神经退行性疾病涉及氧化损伤和金属不平衡,使得LTF成为潜在的治疗目标.
研究的目的:
- 为了识别FDA批准的药物用于调节乳酸活性.
- 为神经退行性疾病制定一个具有成本效益的治疗策略.
主要方法:
- 选了大约3500种FDA批准的药物,使用分子对接对抗乳酸铁素.
- 利用药物分析和PASS分析进行生物活性预测.
- 采用分子动力学模拟,PCA和自由能量景观映射来评估复杂的稳定性和相互作用.
主要成果:
- 确定了十种与乳酸铁素具有高度结合亲和力的药物.
- 莫萨普拉明和昆普拉明表明稳定地与LTF的铁结合口袋结合.
- 药物分析表明神经保护作用,包括抗炎和认知增强.
结论:
- 莫萨普拉和奎努普拉被确定为神经退行性疾病中乳酸铁素的潜在调节剂.
- 计算药物查对于重新定位药物的使用是有效的.
- 这些发现支持进一步实验验证治疗开发.
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

